Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Roivant Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Roivant Sciences Ltd.'s regulatory disclosures and financial reporting.
Roivant Sciences (ROIV) Form 4, filed 1 Aug 2025, discloses a large equity grant to President & Vant Chair Frank Torti. On 30 Jul 2025 he received (i) 1,836,547 time-based RSUs that vest 20 % after one year and quarterly thereafter, and (ii) 11,900,000 performance-based PSUs split into six price-hurdle tranches ($15–$30). Each tranche vests only after both a share-price test (30-day VWAP before 26 Jul 2029) and one additional year of service, followed by a two-year holding lock-up. The award was granted at $0 cost; no open-market buying occurred.
Post-grant, Torti’s beneficial ownership rises to 13,736,547 common shares, all held directly. While the structure tightly links vesting to long-term price performance, full issuance would add material dilution if all hurdles are met.
Roivant Sciences Ltd. (ROIV) – Form 4 filing: President & Immunovant CEO Eric Venker reported an equity award on 30 Jul 2025. The grant comprises 198,413 restricted stock units (RSUs) for common shares at a cost basis of $0. Vesting begins 20 May 2025, with 25 % vesting on the first anniversary and the balance in 12 equal quarterly tranches, contingent upon continued service.
Post-grant, Venker’s direct beneficial ownership rises to 1,660,636 common shares. The filing contains no open-market purchases or sales; therefore, it signals executive retention rather than a valuation view. The transaction represents routine equity compensation and has minimal immediate dilution or cash-flow impact for shareholders.
Roivant Sciences (ROIV) – Form 4 filing (30 Jul 2025)
CFO Richard Pulik reported an automatic disposition of 1,919 common shares on 28 Jul 2025 at an implied price of $11.35. The transaction is coded “F”, indicating the issuer withheld shares to cover taxes due upon the vesting of previously granted restricted stock units (RSUs); no open-market sale occurred. After the net-settlement, Pulik retains 397,553 shares, so the shares surrendered equal roughly 0.5 % of his post-transaction holdings. Because the activity is tax-related and immaterial to overall ownership, it is typically viewed as routine rather than a directional signal on the company’s prospects.
Roivant Sciences (ROIV) – Form 3. President & Vant Chair Frank Torti has filed his initial beneficial-ownership report covering 10.27 million common shares underlying stock options. Exercise prices range from $3.85 to $13.07 with expiry dates between 2028-2032. The largest tranche is 6.03 million options at $3.85 that vest 25% on 20-Apr-2023 and monthly thereafter; all other grants are already fully vested. No non-derivative share holdings were disclosed. The filing confirms Torti’s officer status and records his equity incentives for Section 16 compliance.